Gan & Lee Pharmaceuticals.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| 603087.SS | 1066.HK | MMED | 600867.SS | 000661.SZ | 3759.HK | |
|---|---|---|---|---|---|---|
| Market cap | 43.21B | 15.14B | 5.43B | 15.73B | 30.39B | 55.85B |
| P/E (TTM) | 36.2 | 10.2 | — | 28.7 | — | 27.4 |
| Forward P/E | 38.1 | 8.1 | 27.8 | 22.3 | 6.7 | 17.2 |
| Price/book | 3.6 | 0.5 | 1.5 | 2.1 | 1.3 | 2.8 |
| Dividend yield | 1.39% | 5.23% | — | 3.75% | 0.22% | 0.78% |
| 1-year change | +12.15% | −41.03% | +4.33% | −11.78% | −30.53% | +19.72% |
| Today | +0.47% | +4.81% | +2.33% | +0.25% | +1.78% | +3.47% |
The closest companies by business and industry (Medical Instruments & Supplies). Prices may be delayed up to 15 min.
Latest news
All 603087.SS news ›A New Paradigm for Long-Term Weight Management: Once-Monthly Bofanglutide Maintenance Therapy Delivers Positive Results in Weight Control and Maintenance Over 24 Weeks -- Gan & Lee Pharmaceuticals' GRADUAL-3 Study Meets Its Primary Endpoint
BEIJING and BRIDGEWATER, Mass., Nov. 4, 2026 /CNW/ -- Gan & Lee Pharmaceuticals (Stock Code: 603087. SH) announced positive topline results from GRADUAL-3, a Phase III clinical study evaluating once-monthly administration of its…
From the 4Search news index, newest first.